Efavirenz for treating Creutzfeldt-Jakob disease
Treatments studied
Part of Brain & nervous system, Infections, Mental health clinical trials.
This trial tests whether the drug efavirenz can help people with Creutzfeldt-Jakob disease (a rare brain disorder). The study aims to see if it can slow the disease and improve daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have probable sporadic CJD or a confirmed genetic form of CJD.
- You are between 18 and 80 years old.
- You still have some ability to do daily activities (score above 10 on a function scale).
- You have a caregiver 18 or older who can go with you to study visits.
- You are not taking any medications that conflict with efavirenz, or you can switch to a different medicine.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with chronic viral infections affecting the brain and spinal cord. Researchers will collect spinal fluid samples and track your health over one year to better understand these infections and improve care.
This study collects information from patients diagnosed with Creutzfeldt-Jakob Disease (CJD), a rare brain condition, to better understand how it develops and progresses. Researchers will review your medical records, blood tests, brain scans, and other clinical data to identify patterns that could help future patients.
This study follows people who have a close family member with inherited Creutzfeldt-Jakob disease (CJD) to understand how the disease develops before any symptoms. It may involve genetic testing and safety-required procedures like brain scans and a spinal fluid test to learn about early changes.
This study tests whether switching to a medication called efavirenz can help control HIV. It is for people who have been on stable HIV treatment for years but still have low levels of virus in their blood.
This study looks for early signs of prion disease in people who are at risk, using blood tests, spinal fluid, and thinking tests. It hopes to find ways to diagnose and track the disease earlier.
This Phase 1 study tests whether an existing type of anti-viral medicine (nucleoside reverse transcriptase inhibitors) can help people with early Alzheimer’s disease. It also focuses on safety and proper dosing while measuring brain-related changes and memory-related symptoms.
Hear when a new Creutzfeldt-Jakob Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.